Alefacept, a LFA-3/IgG1 fusion protein that binds to CD2, is the first biologic agent approved by the US Food and Drug Administration (FDA) for the treatment of moderate-to-severe psoriasis in 2003 (Sugiyama et al., 2008). The gene discussed is CD2; the disease is psoriasis.